% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brenner:143636,
      author       = {H. Brenner$^*$ and S. Calderazzo$^*$ and T. Seufferlein and
                      L. Ludwig and N. Dikopoulos and J. Mangold and W. Böck and
                      T. Stolz and T. Eisenbach and T. Block and A.
                      Kopp-Schneider$^*$ and D. Czock and K. Tikk$^*$},
      title        = {{E}ffect of a {S}ingle {A}spirin {D}ose {P}rior to {F}ecal
                      {I}mmunochemical {T}esting on {T}est {S}ensitivity for
                      {D}etecting {A}dvanced {C}olorectal {N}eoplasms: {A}
                      {R}andomized {C}linical {T}rial.},
      journal      = {The journal of the American Medical Association},
      volume       = {321},
      number       = {17},
      issn         = {0098-7484},
      address      = {Chicago, Ill.},
      publisher    = {American Medical Association},
      reportid     = {DKFZ-2019-01213},
      pages        = {1686 - 1692},
      year         = {2019},
      abstract     = {Fecal immunochemical tests for hemoglobin are widely used
                      for colorectal cancer (CRC) screening. Observational studies
                      suggested that sensitivity of fecal immunochemical tests for
                      detecting advanced neoplasms could be increased by
                      acetylsalicylic acid (aspirin), especially among men.To
                      evaluate the potential to increase sensitivity of fecal
                      immunochemical tests by administering a single 300-mg oral
                      aspirin dose 2 days before stool sampling.A randomized,
                      placebo-controlled, double-blind trial was conducted in 14
                      gastroenterology practices and 4 hospitals in Germany, and
                      included 2422 men and women aged 40 to 80 years scheduled
                      for colonoscopy, with no recent use of aspirin or other
                      drugs with antithrombotic effects (enrollment from June 2013
                      to November 2016, and final follow-up January 27,
                      2017).Administration of a single tablet containing 300 mg of
                      aspirin (n = 1208) or placebo (n = 1214) 2 days
                      before fecal sampling for fecal immunochemical test.The
                      primary outcome was sensitivity of a quantitative fecal
                      immunochemical test at 2 predefined cutoffs (10.2 and 17-μg
                      Hb/g stool) for detecting advanced neoplasms (colorectal
                      cancer or advanced adenoma).Among 2422 randomized patients
                      (mean [SD] age, 59.6 [7.9] years; 1219, $50\%,$ men), 2134
                      were included in the analysis $(78\%$ for primary screening
                      colonoscopy, $22\%$ for diagnostic colonoscopy). Advanced
                      neoplasms were identified in 224 participants $(10.5\%),$
                      including 8 participants $(0.4\%)$ with CRC and 216
                      participants $(10.1\%)$ with advanced adenoma. Sensitivity
                      was $40.2\%$ in the aspirin group and $30.4\%$ in the
                      placebo group (difference $9.8\%,$ $95\%$ CI, $-3.1\%$ to
                      $22.2\%,$ P = .14) at cutoff 10.2-μg Hb/g stool and
                      $28.6\%$ in the aspirin and $22.5\%$ in the placebo group
                      (difference $6.0\%,$ $95\%$ CI, $-5.7\%$ to $17.5\%,$
                      P = .32) at cutoff 17-μg Hb/g stool.Among adults aged
                      40 to 80 years not using aspirin or other antithrombotic
                      medications, administration of a single dose of oral aspirin
                      prior to fecal immunochemical testing, compared with
                      placebo, did not significantly increase test sensitivity for
                      detecting advanced colorectal neoplasms at 2 predefined
                      cutoffs of a quantitative fecal immunochemical
                      test.Deutsches Register Klinischer Studien Identifier:
                      DRKS00003252; EudraCT Identifier: 2011-005603-32/DE.},
      cin          = {C070 / C120 / C060 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)C060-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31063574},
      doi          = {10.1001/jama.2019.4755},
      url          = {https://inrepo02.dkfz.de/record/143636},
}